Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Trials
|
October 22, 2021
Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2)
Jack Knorr, Jay L Tuttle, Janelle A Sabo, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
June 14, 2002
Impaired collateral development in mature rats
Jay L Tuttle, Tara L Hahn, Bridget M Sanders, et al.
Crohn'S & Colitis 360
|
May 25, 2026
The UCEIS and UC-100 score were responsive endoscopic and global indices in a phase 2 trial of ulcerative colitis
Sudheer K Vuyyuru, Simon Travis, Soushyant Kiarasi, et al.
Microcirculation (New York, N.Y. : 1994)
|
October 11, 2002
Impaired collateral artery development in spontaneously hypertensive rats
Jay L Tuttle, Bridget M Sanders, Harold M Burkhart, et al.
Clinical and Translational Gastroenterology
|
March 7, 2023
Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study
Boyd Steere, Jochen Schmitz, Nick Powell, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis
William J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Gastroenterology
|
September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
William J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Journal of Hematology & Oncology
|
March 23, 2017
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
Saroj Vadhan-Raj, Rafat Abonour, Jonathan W Goldman, et al.
Gastroenterology
|
November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease
Bruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
Science Translational Medicine
|
June 9, 2022
The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination
Robert J Benschop, Jay L Tuttle, Lin Zhang, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Trials
|
October 22, 2021
Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2)
Jack Knorr, Jay L Tuttle, Janelle A Sabo, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
June 14, 2002
Impaired collateral development in mature rats
Jay L Tuttle, Tara L Hahn, Bridget M Sanders, et al.
Crohn'S & Colitis 360
|
May 25, 2026
The UCEIS and UC-100 score were responsive endoscopic and global indices in a phase 2 trial of ulcerative colitis
Sudheer K Vuyyuru, Simon Travis, Soushyant Kiarasi, et al.
Microcirculation (New York, N.Y. : 1994)
|
October 11, 2002
Impaired collateral artery development in spontaneously hypertensive rats
Jay L Tuttle, Bridget M Sanders, Harold M Burkhart, et al.
Clinical and Translational Gastroenterology
|
March 7, 2023
Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study
Boyd Steere, Jochen Schmitz, Nick Powell, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis
William J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Gastroenterology
|
September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
William J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Journal of Hematology & Oncology
|
March 23, 2017
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
Saroj Vadhan-Raj, Rafat Abonour, Jonathan W Goldman, et al.
Gastroenterology
|
November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease
Bruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
Science Translational Medicine
|
June 9, 2022
The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination
Robert J Benschop, Jay L Tuttle, Lin Zhang, et al.
Page
of 2